The Chemotherapy Question Nobody Asked in Four Major Endometrial Cancer Trials
RUBY, NRG-GY018, AtTEnd, and DUO-E4 all proved immunotherapy works in dMMR endometrial cancer. None of them tested whether chemotherapy...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Protocol Design Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
RUBY, NRG-GY018, AtTEnd, and DUO-E4 all proved immunotherapy works in dMMR endometrial cancer. None of them tested whether chemotherapy...
CRB-913 achieved 5% mean weight loss in Phase 1b obesity trial, with all doses showing statistical significance against placebo...
Lexeo's LX2020 earns FDA RMAT designation for PKP2 cardiomyopathy, enabling expedited development based on interim Phase I/II data.
Five-year lecanemab data shows 62% of early Alzheimer's patients with low tau levels demonstrated cognitive improvement, with widening benefits...
FDA Rejects ivonescimab BLA due to missing overall survival data. Summit Therapeutics' lung cancer therapy blocked despite progression-free survival...
A decade in patient recruitment did not prepare her for what it felt like to be on the other...
Coherus cut 30% of staff; Gyre laid off post-acquisition. Sites lose study contacts, amendments stall, and monitoring gaps widen....
Nature Biotechnology's new FDR taxonomy arrives as omics-driven trials flood FDA submissions, here's what every biomarker strategist must understand...
At the device session of the FDA and Duke-Margolis rare disease workshop: why BCI trials resist blinding at a...
VK2735 moves 75% of patients down BMI category in 13 weeks, with systolic blood pressure and triglycerides also improving...